Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden
Vikström, Sofi ; Mikiver, Rasmus ; Lapins, Jan ; Nielsen, Kari LU
; Vassilaki, Ismini
; Lyth, Johan
; Isaksson, Karolin
LU
and Eriksson, Hanna
(2023)
In The British journal of dermatology
189(6).
p.702-709
- Abstract
BACKGROUND: The melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden.
OBJECTIVES: To analyse the incidence and MSS time trends between 1990 and 2020 in Sweden.
METHODS: Nationwide, population-based, and prospectively collected clinico-pathological data on invasive CM from the Swedish Melanoma Registry (SweMR) were analysed for survival trends between 1990 and 2020 by using Kaplan-Meier curves and Cox Proportional Hazard ratios.
RESULTS: In total, 77 036 primary invasive CM were diagnosed in 70 511 patients in Sweden between 1990 and... (More)
BACKGROUND: The melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden.
OBJECTIVES: To analyse the incidence and MSS time trends between 1990 and 2020 in Sweden.
METHODS: Nationwide, population-based, and prospectively collected clinico-pathological data on invasive CM from the Swedish Melanoma Registry (SweMR) were analysed for survival trends between 1990 and 2020 by using Kaplan-Meier curves and Cox Proportional Hazard ratios.
RESULTS: In total, 77 036 primary invasive CM were diagnosed in 70 511 patients in Sweden between 1990 and 2020. The 5-year MSS was 88.9% (88.3-89.4) 1990-2000, 89.2% 2001-2010, and 93.0% (92.7-93.9) 2011-2020. The odds ratios for being diagnosed with nodular melanomas (vs. superficial spreading melanoma) was significantly reduced by 20% (2001-2010) and by 46% (2011-2020 vs. 1990-2000). Overall, the MSS improved over both diagnostic periods (2001-2010 and 2011-2020) vs the reference period 1990-2000 among men and women, respectively, (HRmen, 2001-2010: 0.89, 95% CI 0.82-0.96; HRmen, 2011-2020: 0.62, 95% CI 0.56-0.67. HRwomen, 2001-2010: 0.82, 95% CI 0.74-0.91; HRwomen, 2011-2020: 0.62, 95% CI 0.56-0.70). The risk of CM-death was significantly lower in all age groups for both men and women in the most recent diagnostic period (2011-2020 vs. 1990-2000).
CONCLUSIONS: The results are emphasizing the improved MSS among both men and women in Sweden. The MSS improvements, specifically for the period 2011-2020, may be correlated to the introduction of new systemic therapies and are here shown for the first time in detail for Sweden.
(Less)
- author
- Vikström, Sofi
; Mikiver, Rasmus
; Lapins, Jan
; Nielsen, Kari
LU
; Vassilaki, Ismini
; Lyth, Johan
; Isaksson, Karolin
LU
and Eriksson, Hanna
- organization
- publishing date
- 2023-07-18
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The British journal of dermatology
- volume
- 189
- issue
- 6
- pages
- 14 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85178161917
- pmid:37463416
- ISSN
- 1365-2133
- DOI
- 10.1093/bjd/ljad244
- language
- English
- LU publication?
- yes
- additional info
- © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.
- id
- affc86b1-9130-4578-8c15-389fbdd1a8b4
- date added to LUP
- 2023-08-16 13:32:57
- date last changed
- 2024-04-19 00:18:41
@article{affc86b1-9130-4578-8c15-389fbdd1a8b4,
abstract = {{<p>BACKGROUND: The melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden.</p><p>OBJECTIVES: To analyse the incidence and MSS time trends between 1990 and 2020 in Sweden.</p><p>METHODS: Nationwide, population-based, and prospectively collected clinico-pathological data on invasive CM from the Swedish Melanoma Registry (SweMR) were analysed for survival trends between 1990 and 2020 by using Kaplan-Meier curves and Cox Proportional Hazard ratios.</p><p>RESULTS: In total, 77 036 primary invasive CM were diagnosed in 70 511 patients in Sweden between 1990 and 2020. The 5-year MSS was 88.9% (88.3-89.4) 1990-2000, 89.2% 2001-2010, and 93.0% (92.7-93.9) 2011-2020. The odds ratios for being diagnosed with nodular melanomas (vs. superficial spreading melanoma) was significantly reduced by 20% (2001-2010) and by 46% (2011-2020 vs. 1990-2000). Overall, the MSS improved over both diagnostic periods (2001-2010 and 2011-2020) vs the reference period 1990-2000 among men and women, respectively, (HRmen, 2001-2010: 0.89, 95% CI 0.82-0.96; HRmen, 2011-2020: 0.62, 95% CI 0.56-0.67. HRwomen, 2001-2010: 0.82, 95% CI 0.74-0.91; HRwomen, 2011-2020: 0.62, 95% CI 0.56-0.70). The risk of CM-death was significantly lower in all age groups for both men and women in the most recent diagnostic period (2011-2020 vs. 1990-2000).</p><p>CONCLUSIONS: The results are emphasizing the improved MSS among both men and women in Sweden. The MSS improvements, specifically for the period 2011-2020, may be correlated to the introduction of new systemic therapies and are here shown for the first time in detail for Sweden.</p>}},
author = {{Vikström, Sofi and Mikiver, Rasmus and Lapins, Jan and Nielsen, Kari and Vassilaki, Ismini and Lyth, Johan and Isaksson, Karolin and Eriksson, Hanna}},
issn = {{1365-2133}},
language = {{eng}},
month = {{07}},
number = {{6}},
pages = {{702--709}},
publisher = {{Wiley-Blackwell}},
series = {{The British journal of dermatology}},
title = {{Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden}},
url = {{http://dx.doi.org/10.1093/bjd/ljad244}},
doi = {{10.1093/bjd/ljad244}},
volume = {{189}},
year = {{2023}},
}